By /

New dementia insights this week in Memory Matters Weekly #14: early tau drug trials, a shift in Alzheimer’s treatment strategy, and community-based dementia care.

Published Monday, 15 December -Issue #14

3 Quick Bites: Last Week in Dementia News

  1. Alzheimer’s Drug Development Is Shifting Toward Multi-Target Approaches
  2. New Alzheimer’s Drug Targeting Tau Begins Early Human Trials
  3. New Dementia Care Model Combines Nature, Community and Daily Life

Alzheimer’s Drug Development Is Shifting Toward Multi-Target Approaches

Reuters • 12 Dec 2025 • Read it here

Story:
Reuters reports that Alzheimer’s drug developers are rethinking how treatments are designed. The article explains that Alzheimer’s is super complex, with many pathways involved, kind of like cancer was before they started using targeted therapies. After years of failed trials targeting single proteins like amyloid or tau, researchers are increasingly looking to multi-target approaches, inspired by how cancer is treated. Instead of focusing on just one protein like amyloid, scientists are now developing drugs that attack several factors.

Why it matters:
This helps explain why progress in dementia drugs has been slow. Alzheimer’s isn’t driven by one single mechanism, so treating it that way may never be enough. Current drugs for Alzheimer’s only slow progression by about 30%, and they don’t work equally well for everyone. Experts believe that hitting multiple targets, maybe with one drug or a combo, could be the key to really slowing the disease down.

My take:
I’m really encouraged by this direction since Alzheimer’s is so tricky, and a one-size-fits-all drug just hasn’t worked well enough. Seeing companies learn from cancer research feels like a smart move, though some trials have flopped, others are years from results. Still, this multi-pronged approach could be the key to cracking open more personalized, powerful treatments down the line.

New Alzheimer’s Drug Targeting Tau Begins Early Human Trials

Business Wire • 8 Dec 2025 • Read it here

Story:
A new experimental Alzheimer’s drug called ARO-MAPT has entered early human trials. The drug targets tau, one of the proteins linked to brain cell damage in Alzheimer’s and related dementias. This treatment uses RNA-based technology designed to reduce tau production directly inside brain cells. The idea is that by stopping or reducing the build-up of toxic tau tangles in the brain, this drug could slow or even prevent the disease from getting worse in people with early Alzheimer’s. It’s delivered through a subcutaneous injection, and their technology apparently gets it across the blood-brain barrier, which is a big deal. They’ve dosed the first subjects already, and they’re testing it in both healthy volunteers and patients, with initial results expected in the second half of 2026.

Why it matters:
Tau protein buildup is believed to be a key driver of brain damage in Alzheimer’s and related diseases, so ARO-MAPT could potentially slow or stop disease progression by reducing this toxic accumulation. Arrowhead’s trial, which includes both healthy volunteers and early Alzheimer’s patients, uses a unique delivery system to cross the blood-brain barrier, a major challenge in brain therapies. It’s early, but if successful, this give us something that tackles the disease at its root. Plus, it’s part of a broader wave of RNAi therapies that could open doors for other tough diseases.

My take:
This isn’t a breakthrough yet, but it’s another sign that researchers are still pushing forward on tau, not giving up after earlier disappointments. If ARO-MAPT can slow down or stop the tau build-up in the brain, it might mean more time before things get really hard, or even preserve some of their memory and abilities longer. It’s still in the very early stages, results aren’t coming until late 2026 at the earliest, and even then, it could be years before it’s available, assuming it passes all the hurdles.

New Dementia Care Model Combines Nature, Community and Daily Life

Simon Fraser University • 8 Dec 2025 • Read it here

Story:
Researchers in Canada are exploring a dementia care model inspired by a model from the Netherlands called the “Green Care Farm.” Basically, it’s about creating small, home-like settings on farms where people with dementia can live and participate in everyday activities like gardening or helping with animals. The idea is to make life feel more normal and meaningful, rather than being in a traditional care facility. They’ve been testing this out in British Columbia with a pilot project, and the early feedback from families and caregivers is that it’s making a big difference in quality of life.

Why it matters:
There’s growing evidence that surroundings shape how people live with dementia. Calm spaces, access to nature and a meaningful routine can make a real difference to quality of life. This research helps explain why community-based models appeal to families and clinicians alike, especially when traditional care environments feel restrictive or impersonal.

My take:
I wrote recently about my hesitation around dementia villages. This research doesn’t erase those concerns, but it does help clarify why elements of these models matter.

For me, the takeaway is that the environment matters, and so does autonomy. Any model built around nature and community still needs transparency, access and real choice. Design can support dignity, but it shouldn’t replace it.

GET A FREE MINI DEMENTIA ACTIVITY BOOK!

Enter your email below, confirm your email, & we'll send it straight to your inbox!

Don't forget to confirm your email and consent to receive emails from us to receive the free booklet!